Clinical Trials on Hemoglobinopathies in Italy

Total 96 results

Società Italiana Talassemie ed Emoglobinopatie

Recruiting

STUDY INCIDENCE AND CHARACTERISTICS OF MALIGNANT NEOPLASIES IN PATIENTS WITH HEMOGLOBINOPATHY FOLLOWED IN ITALY (Tum001)

Malignacy, Hemoglobinopathie

Italy
Società Italiana Talassemie ed Emoglobinopatie

Recruiting

Observational Study for Patients With Hemoglobinopathies and Rare Inherited Anemia and Covid 19

Haemoglobinopathies

Italy
Azienda Ospedaliera V. Cervello

Unknown

Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies (IFNRIBAHE)

Hemoglobinopathies

Italy
Università degli Studi di Ferrara

Completed

Impact of the Preparation Method of Red Cell Concentrates on Transfusion Indices in Thalassemic Patients

Thalassemia Major

Italy
Federico II University

Completed

The Role of OCTA in Patients Affected by Beta Thalassemia

Thalassemia

Italy
Società Italiana Talassemie ed Emoglobinopatie
Associazione Italiana de Ematologia e Oncologia Pediatrica; Società Italiana...

Completed

Transfusion Treatment in Patients With SCD

Anemia, Sickle Cell

Italy
IRCCS San Raffaele
Telethon Institute for Gene Therapy (OSR-TIGET)

Active, not recruiting

Long-term Follow-up of Subjects Treated With OTL-300 for Transfusion Dependent Beta-thalassemia Study (TIGET-BTHAL)

Beta Thalassaemia

Italy
Rare Partners srl Impresa Sociale
Università degli Studi di Ferrara

Completed

Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (SIRTHALACLIN)

Beta-Thalassemia

Italy
IRCCS San Raffaele
Orchard Therapeutics; Fondazione Telethon

Unknown

Gene Therapy for Transfusion Dependent Beta-thalassemia (TIGET-BTHAL)

Beta-Thalassemia

Italy
medac GmbH
Syneos Health; Celerion; Venn Life Sciences

Completed

Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases

Bone Marrow Failure Syndromes | Inborn Errors of Metabolism | Primary Immunodeficiencies | Haemoglobinopathies

Poland, Czechia, Germany, Italy
Royal Brompton & Harefield NHS Foundation Trust
CORDA, The Heart Charity; Apotex Inc.; The Cooley's Anemia Foundation,; The UK...

Unknown

Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major

Beta-Thalassemia

Italy
Azienda Ospedaliera V. Cervello

Completed

Efficacy Study of the Use of Sequential DFP-DFO Versus DFP (SEQDFPDFO)

Beta-Thalassemia | Thalassemia Major

Italy
San Luigi Gonzaga Hospital

Completed

Avascular Bone Necrosis in Sickle Cell Disease: a Pediatric Study. (OsteoSCD)

Sickle Cell Disease

Italy
Società Italiana Talassemie ed Emoglobinopatie

Completed

Vitamin D and Bisphosphonates in the Treatment of Sickle Cell Disease

Sickle Cells Disease

Italy
Novartis Pharmaceuticals

Completed

Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec

Beta Thalassemia Transfusion Dependent

Italy
Cerus Corporation

Completed

Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion

Thalassemia Major

Turkey, Italy
University of Campania "Luigi Vanvitelli"

Completed

Endocrine Function During Deferasirox Therapy

Iron Overload | Endocrine; Complications | Transfusion-dependent Thalassemia

Italy
University Hospital of Ferrara

Recruiting

Atrial Fibrillation in Beta-Thalassemia

Atrial Fibrillation | Thalassemia

Italy
Università degli Studi di Ferrara
Azienda Ospedaliero, Universitaria Pisana; Rare Partners srl Impresa Sociale; Azienda Ospedaliero, Universitaria Meyer

Recruiting

Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (THALA-RAP) (THALA-RAP)

Beta-Thalassemia

Italy
Hospital Universitari Vall d'Hebron Research Institute

Active, not recruiting

GenoMed4ALL: Improving SCD Classification and Prognosis by AI (GenoMed4ALL)

Sickle Cell Disorders

Spain, Netherlands, France, Italy
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

ACE-536 Extension Study - Beta Thalassemia

Beta-Thalassemia

Greece, Italy
Consorzio per Valutazioni Biologiche e Farmacologiche
European Commission

Completed

Pharmacokinetic Study of Deferiprone in Paediatric Patients (DEEP-1)

Chronic Iron Overload

Italy, Cyprus, Egypt
Ospedale Microcitemico
Azienda Sanitaria Locale di Cagliari

Completed

Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major (DFODFPTM)

Iron Overload | Cardiomyopathy

Italy
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia

B-Thalassemia

Italy, Greece
Hoffmann-La Roche

Completed

A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia

Beta-Thalassemia

Italy, Lebanon, Thailand
Azienda Ospedaliero-Universitaria di Modena

Recruiting

"Iron Overload and Endocrinological Diseases"

Iron Overload | Hemochromatosis | Thalassemia Major | Thalassemia Intermedia | Endocrinopathy

Italy
Novartis Pharmaceuticals

Completed

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

Transfusional Iron Overload | β-thalassemia

Italy
University of Milano Bicocca

Completed

Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases (ThalaCoV)

Covid19 | Thalassemia Major

Italy
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.

Thalassemia Major

Thailand, Turkey, Italy, Lebanon, Greece
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Hematologic Diseases | Genetic Diseases, Inborn | Hemoglobinopathies | Thalassemia | Beta-Thalassemia

United States, Germany, Italy, United Kingdom, Canada
AstraZeneca

Completed

PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4) (HESTIA4)

Sickle Cell Disease

Belgium, United Kingdom, Italy, Spain, Kenya, Lebanon
ApoPharma

Completed

Efficacy Study in Removing Excess Iron From the Heart

Hemosiderosis | Thalassemia Major

Greece, Italy
Novartis Pharmaceuticals

Completed

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

Transfusional Iron Overload | β-thalassemia Major | Pediatric Rare Anemia

Italy, France
Ente Ospedaliero Ospedali Galliera
University of Campania "Luigi Vanvitelli"; Reggio Calabria; Ospedale Maggiore... and other collaborators

Completed

Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI (Nerixia)

Osteoporosis | Thalassemia Major | Thalassemia Intermedia

Italy
Celgene

Completed

To Document the Burden of Illness on the Quality of Life and the Impact on Healthcare Utilization in (Beta) β-thalassemia Subjects Who Are Transfusion Dependent (TD) and Non-transfusion Dependent (NTD) Receiving Standard of Care

Beta-Thalassemia

Greece, Italy, Lebanon, Thailand, Turkey
Terumo BCTbio
United States Department of Defense; U.S. Army Medical Research and Development... and other collaborators

Terminated

Efficacy and Safety of RBCs Derived From Mirasol-treated Whole Blood in Patients Requiring Chronic Transfusion (PRAISE) (PRAISE)

Transfusion Dependent Thalassemia

United States, Israel, Italy, Turkey
Celgene

Terminated

Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.

Beta Thalassemia Intermedia | Beta Thalassemia Major

France, United Kingdom, Italy, Greece
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Completed

A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia (BEYOND)

Thalassemia

United States, Greece, Italy, Lebanon, Thailand, United Kingdom
bluebird bio

Completed

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

Beta-Thalassemia

France, United Kingdom, United States, Thailand, Italy, Germany
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

Sickle Cell Disease | Hemoglobinopathies | Hematological Diseases | Hydroxyurea Failure | Hydroxyurea Intolerance

United States, Italy, United Kingdom, Germany
bluebird bio

Completed

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia

Beta-Thalassemia

United States, Germany, United Kingdom, France, Greece, Italy
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia (THETIS)

Non-transfusion Dependent Thalassemia

Thailand, Turkey, Italy, Greece, China, United Kingdom, Lebanon, Tunisia
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia

Hematologic Diseases | Genetic Diseases, Inborn | Hemoglobinopathies | Thalassemia | Beta-Thalassemia

United States, United Kingdom, Canada, Germany, Italy
Ente Ospedaliero Ospedali Galliera

Completed

Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia (PAH2010)

Pulmonary Arterial Hypertension | Thalassemia Major | Thalassemia Intermedia

Italy
Consorzio per Valutazioni Biologiche e Farmacologiche
European Commission

Completed

Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients

Chronic Iron Overload

Italy, United Kingdom, Egypt, Greece, Cyprus, Albania, Tunisia
Società Italiana Talassemie ed Emoglobinopatie

Completed

Hydroxyurea in the Treatment of Sickle Cell Disease

Sickle Cell Disease

Italy
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Hematologic Diseases | Genetic Diseases, Inborn | Sickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Thalassemia | Beta-Thalassemia

United States, Italy, Germany, Saudi Arabia
Vifor (International) Inc.
Labcorp Corporation of America Holdings, Inc

Completed

Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia (VITHAL)

Beta-Thalassemia | Non-transfusion-dependent Thalassemia

Greece, Israel, Italy, Lebanon, Thailand
Shire

Terminated

Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload

Beta-Thalassemia | Transfusional Iron Overload

United States, Lebanon, Canada, Italy, Turkey
Pfizer

Completed

Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease

Phase 1 Sickle Cell

United States, United Kingdom, Belgium, Netherlands, Italy

Clinical Trials on Hemoglobinopathies in Italy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations